Nanobiotix SA (FR:NANO)
:NANO
Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€28.70
<€0.01(0.14%)
At close: 4:00 PM EST
€28.70
<€0.01(0.14%)
Day’s Range― - ―
52-Week Range€3.76 - €47.66
Previous CloseN/A
Volume30.64K
Average Volume (3M)654.19K
Market Cap
€1.43B
Enterprise Value€1.76B
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside91.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.19
Revenue Forecast (FY)€34.72M
Bulls Say, Bears Say
Bulls Say
Nondilutive Financing & RunwayThe $71M nondilutive royalty facility and year-end €52.8M cash materially extend operating runway into early 2028, lowering near-term dilution risk and giving management time to realize clinical readouts or partner milestones that can unlock value without immediate equity raises.
Lower R&D SpendA ~43% reduction in R&D spend reflects structural cost relief after transferring certain obligations, improving free cash flow trajectory and allowing capital to be reallocated toward highest-priority programs or platform development while preserving runway for clinical catalysts.
Strategic J&J CollaborationHanding Phase III sponsorship to Janssen shifts development cost, operational burden and regulatory execution to a global pharma, de-risking Nanobiotix's cash exposure while preserving milestone/royalty upside and potentially accelerating development through partner scale and expertise.
Bears Say
Negative Shareholders' EquityPersistent negative equity and rising debt materially weaken financial flexibility, constrain borrowing capacity, and increase sensitivity to adverse outcomes; this structural capital weakness raises the probability of future dilutive financings or onerous funding terms.
Runway Contingent On TrancheProjected runway depends on a contingent $21M payment; failure or delay would shorten runway and force earlier external funding, increasing dilution or cost of capital. This reliance on single-tranche timing is a durable financing risk until secured.
Dependence On J&J DecisionsWith Janssen controlling late-stage development and filing choices, Nanobiotix cedes timing, indication strategy and some commercial optionality, limiting its ability to steer program prioritization or capture full upside and making outcomes dependent on partner priorities.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €3.75 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.43B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 110 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. is a clinical-stage biotechnology firm dedicated to advancing novel therapeutic solutions for various forms of cancer. At the forefront of its pipeline is NBTXR3, an innovative sterile aqueous suspension crafted from crystalline hafnium oxide nanoparticles. This agent is being developed to address a broad spectrum of malignancies, including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancers. Nanobiotix S.A. has established a strategic alliance with LianBio to facilitate the development and market introduction of NBTXR3 across several key Asian territories: Greater China, South Korea, Singapore, and Thailand. The company, which was established in 2003, maintains its corporate headquarters in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(91.64% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---